col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


34 Ergebisse       Seite 1

 [1] 
Wiley: Clinical & Experimental Immunology
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2024―Dez―11 Reduced response to SARS-CoV-2 vaccination is associated with impaired immunoglobulin class switch recombination in SLE patients Guillem Montamat, Claire E Meehan, Hannah F Bradford, Reşit Yıldırım, Francisca Guimarães, Marina Johnson, et al. (+3)
2 [GO] 2024―Jul―17 Human Genetic and Immunological Determinants of SARS-CoV-2 Infection and Multisystem Inflammatory Syndrome in Children Halima Kholaiq, Yousra Abdelmoumen, Abderrahmane Moundir, Assiya El Kettani, Fatima Ailal, Ibtihal Benhsaien, et al. (+5)
3 [GO] 2024―Jul―02 Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19 Elena Woods, Adriana Mena, Sophie Sierpinska, Emily Carr, Richard Hagan, John Crowley, et al. (+5)
4 [GO] 2024―Mai―02 Follow-up of Immune Response in Patients with Common Variable Immunodeficiency following SARS-CoV-2 Vaccination Juan Francisco Gutiérrez-Bautista, Irene Díaz-Alberola, María Tarriño, María Aguilera, Fernando Cobo, Juan Antonio Reguera, et al. (+4)
5 [GO] 2024―Apr―20 Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery Mohammad Ali, Stephanie Longet, Isabel Neale, Patpong Rongkard, Forhad Uddin Hassan Chowdhury, Jennifer Hill, et al. (+28)
6 [GO] 2023―Aug―11 Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19 Rohan Ameratunga, Emily Mears, Euphemia Leung, Russell Snell, See-Tarn Woon, William Kelton, et al. (+7)
7 [GO] 2023―Jun―20 Efficacy and safety of MAS825 (anti-IL-1ꞵ/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function Alex D Hakim, Mustafa Awili, Hollis R O’Neal, Omar Siddiqi, Naseem Jaffrani, Richard Lee, et al. (+21)
8 [GO] 2023―Jun―14 Identification of differences in the magnitude and specificity of SARS-CoV-2 nucleocapsid antibody responses in naturally infected and vaccinated individuals Pradeep D Pushpakumara, Chandima Jeewandara, Farha Bary, Deshan Madushanka, Lahiru Perera, Inoka Sepali Aberathna, et al. (+8)
9 [GO] 2023―Apr―25 SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection Kerensa E Ward, Lora Steadman, Abid R Karim, Gary M Reynolds, Matthew Pugh, Winnie Chua, et al. (+9)
10 [GO] 2023―Apr―19 New insights of antineutrophil cytoplasmic antibody-associated vasculitis from the perspective of COVID-19 vaccination Yang Yang, Yi Xiong, Gaosi Xu
11 [GO] 2023―Apr―18 Plasmablasts in previously immunologically naïve COVID-19 patients express markers indicating mucosal homing and secrete antibodies cross-reacting with SARS-CoV-2 variants and other beta-coronaviruses Anna Lundgren, Susannah Leach, Hannes Axelsson, Pauline Isakson, Kristina Nyström, Lydia Scharf, et al. (+7)
12 [GO] 2023―Mrz―04 Down-regulation of MALAT1 is a hallmark of tissue and peripheral proliferative T cells in COVID-19 Shoumit Dey, Helen Ashwin, Luke Milross, Bethany Hunter, Joaquim Majo, Andrew J Filby, et al. (+3)
13 [GO] 2023―Feb―21 Evaluation of QuantiFERON SARS-CoV-2 interferon- release assay following SARS-CoV-2 infection and vaccination Síle A Johnson, Eloise Phillips, Sandra Adele, Stephanie Longet, Tom Malone, Chris Mason, et al. (+18)
14 [GO] 2023―Feb―02 Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K Aley, Sandra Belij-Rammerstorfer, Sagida Bibi, et al. (+31)
15 [GO] 2022―Dez―08 The role of antigen availability during B cell induction and its effect on sustained memory and antibody production after infection and vaccination - Lessons learned from the SARS-CoV-2 pandemic Stefanía P Bjarnarson, Siggeir F Brynjólfsson
16 [GO] 2022―Aug―16 COVID-19 infection and vaccination in immunodeficiency Eva Piano Mortari, Federica Pulvirenti
17 [GO] 2022―Jun―26 Risk Stratification through Allergy History: Single-centre Experience of Specialised COVID-19 Vaccine Clinic Daniel Lyons, Cliodhna Murray, Siobhan Hannigan, Jacklyn Sui, Salma Alamin, Niall Conlon, et al. (+6)
18 [GO] 2022―Mai―06 Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers Eloise Phillips, Sandra Adele, Tom Malone, Alexandra Deeks, Lizzie Stafford, Susan L Dobson, et al. (+12)
19 [GO] 2022―Jan―31 Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the United Kingdom Adrian M Shields, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, et al. (+56)
20 [GO] 2022―Jan―27 Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222 Deshni Jayathilaka, Chandima Jeewandara, Laksiri Gomes, Tibutius Thanesh Pramanayagam Jayadas, Achala Kamaladasa, Gayasha Somathilake, et al. (+14)
21 [GO] 2022―Jan―12 Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA Carly Rich, Daniel Eriksson, Fabrizio Dolfi, Katarzyna Jablonska, Firas Dabbous, Jameel Nazir
22 [GO] 2022―Jan―12 Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals? David Baker, Amy MacDougall, Angray S Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
23 [GO] 2022―Jan―12 T cell responses to SARS-CoV-2 in healthy controls and primary immunodeficiency patients Arnold Awuah, Ava Zamani, Fariba Tahami, Mark Davis, Louis Grandjean, Matthew Buckland, Kimberly Gilmour
24 [GO] 2022―Jan―12 SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study Adrian M Shields, Srinivasan Venkatachalam, Salim Shafeek, Shankara Paneesha, Mark Ford, Tom Sheeran, et al. (+17)
25 [GO] 2021―Jun―01 Human CD4 + T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential Johan Verhagen, Edith D. van der Meijden, Vanessa Lang, Andreas E. Kremer, Simon Völkl, Andreas Mackensen, et al. (+2)
26 [GO] 2021―Feb―05 Innate and Adaptive Immune Responses to SARS-CoV-2 in Humans: Relevance to Acquired Immunity and Vaccine Responses Stanley C. Jordan
27 [GO] 2020―Nov―13 Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain. Sergi Cantenys-Molina, Eduardo Fernández-Cruz, Paloma Francos, Juan C Lopez Bernaldo de Quirós, Patricia Muñoz, Juana Gil-Herrera
28 [GO] 2020―Okt―30 A year in our understanding of COVID-19 R. S. Thwaites
29 [GO] 2020―Sep―26 Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage Sandra Amor, Laura Fernández Blanco, David Baker
30 [GO] 2020―Sep―17 Vaccines for COVID-19 John S. Tregoning, Emily S. Brown, Hannah M. Cheeseman, Katie E. Flight, Sophie L. Higham, Nana-Marie Lemm, et al. (+4)
31 [GO] 2020―Aug―28 Factors determining COVID-19 pneumonia severity in a country with routine BCG vaccination Kurtuluş Aksu, Tuğba Naziroğlu, Pınar Özkan
32 [GO] 2020―Jul―24 Characteristics and roles of SARS-CoV-2 specific antibodies in patients with different severities of COVID-19 Zhifeng Huang, Hao Chen, Mingshan Xue, Huimin Huang, Peiyan Zheng, Wenting Luo, et al. (+3)
33 [GO] 2020―Jul―16 COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases David Baker, Charles AK Roberts, Gareth Pryce, Angray S Kang, Monica Marta, Saul Reyes, et al. (+3)
34 [GO] 2020―Mai―04 Using IL-2R/lymphocyte for predicting the clinical progression of patients with COVID-19 Hongyan Hou, Bo Zhang, Hui Huang, Ying Luo, Shiji Wu, Guoxing Tang, et al. (+5)
 [1] 

34 Ergebisse       Seite 1


[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec